| AFP | Alpha fetoprotein |
| Ag/Ab | Antigen/antibody test |
| AIDS | Acquired immunodeficiency syndrome |
| AOD | Alcohol and other drugs |
| ART | Antiretroviral therapy |
| ARV | Antiretroviral |
| BBVs | Blood- bome viruses |
| CK | Creatine kinase |
| eGFR | Estimated glomerular filtration rate |
| EUC | Electrolytes, Urea, Creatinine |
| FBC | Full Blood Count |
| FTC | Emtricitabine |
| GP | General practitioner |
| HBV | Hepatitis virus |
| hCG | Human chorionic gonadotropin |
| HCV | Hepatitis c virus |
| HCW | Healthcare worker |
| HIV | Human immunodeficiency virus |
| HPC | High-prevalence country |
| IAI | Insertive anal intercourse |
| PrEx | Pre Exposure Prophylaxis Initiative |
| IVI | Insertive vaginal intercourse |
| LFT | Liver Function Test |
| MSM | Men who have sex with men |
| PBS | Pharmaceutical Benefits Scheme |
| urinary PCR | urine protein creatinine ratio |
| PEP | Post-exposure prophylaxis |
| PrEP | Pre exposure prophylaxis |
| PWID | People who inject drugs |
| RAI | Receptive anal intercourse |
| RVI | Receptive vaginal intercourse |
| s100 | A section of the Pharmaceutical Benefits Scheme which provides access to highly specialised drugs |
| Source individual | A person whose blood or other bodily substance may be a source of HIV exposure |
| STI | Sexually transmissible infection |
| TAF | Tenofovir alafenamide |
| TD | Tenofovir disoproxil |
| TDF | Tenofovir disoproxil furnarate |
| TGA | Therapeutic Goods Administration |
| TGD | Trans and gender diverse |
| U=U | Undetectable equals untransmissable |
| Viraemic | a 200 copies/ml of HIV detected on a blood test |
| VL | Viral load |
| WB | Western blot assay |
Acknowledgement of Country